Neoadjuvant chemotherapy for newly diagnosed ovarian cancer: It's all about selection

highlights

 •Patients that cannot be optimal cytoreduced can be offered neoadjuvant chemotherapy. 
•When appropriately used, neoadjuvant chemotherapy reduces postoperative morbidity. 
•Clinical trials are needed to optimize treatment with neoadjuvant chemotherapy.

Purchase access to this article

• $35.95 USD|PDF Download and 24 Hours Online Access